Edition:
United Kingdom

People: Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

108.54USD
9:00pm BST
Change (% chg)

$1.14 (+1.06%)
Prev Close
$107.40
Open
$106.66
Day's High
$109.42
Day's Low
$106.63
Volume
808,649
Avg. Vol
705,146
52-wk High
$141.81
52-wk Low
$92.57

Friedman, Paul 

Dr. Paul A. Friedman is Independent Director of the Alexion Pharmaceuticals, Inc. He served as Chairman of the Board of Directors and Chief Executive Officer of Madrigal Pharmaceuticals. Dr. Friedman served as the CEO and a Director of Incyte Corporation from November 2001 until his retirement in January 2014. He served as President of Research & Development for the DuPont-Merck Pharmaceutical Company, and also as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. He has also held executive and R&D positions with DuPont Pharmaceuticals Research Laboratories, Merck Research Laboratories, and Merck Sharp & Dohme Corporation. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.

Basic Compensation

Total Annual Compensation, USD 95,000
Restricted Stock Award, USD 253,858
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 348,858

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Brennan

448,858

Ludwig Hantson

16,490,200

Paul Clancy

5,486,510

Indrani Franchini

--

Ellen Chiniara

--

Anne-Marie Law

5,296,490
As Of  31 Dec 2018